Tag: Ovarian Cancer Treatment
Tislelizumab Plus Sitravatinib Demonstrates Antitumor Activity, Maintains Safety in Platinum-Resistant Epithelial Ovarian Cancer
April 14, 2021 3:00 pmFor patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
Cancer Discovery Could Revive Failed Treatments for Solid Tumors
April 5, 2021 11:00 amNew research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
What to Know About Telehealth for Ovarian Cancer
April 2, 2021 1:30 am
Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer
March 26, 2021 1:00 pmIxabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more
HIPEC Combo Doubles PFS in Advanced Ovarian Cancer
March 26, 2021 12:00 pmCisplatin/paclitaxel boosts outcomes without increasing complications in registry study.
By Charles Bankhead
Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.
Median progression-free survival (PFS) doubled … Read more
Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer
March 22, 2021 4:00 pmBy Chase Doyle
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more
PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status
March 22, 2021 3:00 pmBy Chase Doyle
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more
Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer
March 21, 2021 5:00 pmResponses in 37% of patients with AVB-500, higher without prior bevacizumab.
By Charles Bankhead
More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more
Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19
March 21, 2021 4:00 pmAlthough some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due … Read more
PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer
March 20, 2021 4:00 pmModest improvement in PFS with rucaparib but worse outcome for reversion mutation.
By Charles Bankhead
A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.
Treatment with rucaparib (Rubraca) … Read more
High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers
March 16, 2021 6:00 pmHigh tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.
The findings suggest that … Read more
Two Pathways, One Destination: Promising Drug Combination to Treat Ovarian Cancer
March 15, 2021 3:00 pmBy R. Colon-Thillet
Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more
FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer
March 3, 2021 4:00 pmThe FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.
By Courtney Marabella
The FDA has granted priority review to the new
REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer
February 25, 2021 5:00 pmFor cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more
Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue
February 24, 2021 6:00 pmAn independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer
February 23, 2021 6:00 pmBy Matthew Stenger
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more
How Biomarker Testing May Help Women Battling Ovarian Cancer
February 18, 2021 6:00 pmReceiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.
By
Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of
… Read more
Proton Therapy Induces Biologic Response to Attack Treatment-Resistant Cancers
February 17, 2021 4:00 pmMayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in … Read more
Improving Cancer Immunotherapy by Blocking Glucose Supply
February 17, 2021 11:00 amAll cells use sugar as a vital source of energy and building blocks. Unfortunately, that means even cancer cells use sugar. Researchers at Memorial Sloan Kettering (MSK) Cancer Center wondered what happens when tumor cells and immune cells battle for … Read more